Evidence map›Paper›PMID 38529496›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Evaluation of cerebrospinal fluid alpha-synuclein seed amplification assay in PSP and CBS.

D P Vaughan, R Fumi, M Theilmann Jensen, T Georgiades, L Wu, D Lux, R Obrocki, J Lamoureux, O Ansorge, Ksj Allinson and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 2 countries.

D P Vaughan
R Fumi
M Theilmann Jensen
T Georgiades
L Wu
D Lux
R Obrocki
J Lamoureux
O Ansorge
Ksj Allinson
T T Warner
Z Jaunmuktane
A Misbahuddin
P N Leigh
Bcp Ghosh
K P Bhatia
A Church
C Kobylecki
Mtm Hu
J B Rowe
C Blauwendraat
H R Morris
E Jabbari
National Hospital for Neurology and Neurosurgery · GBMRC Cognition and Brain Sciences Unit · GBUniversity of Oxford · GBAmprion (United States) · USBrighton and Sussex Medical School · GBManchester Academic Health Science Centre · GBNational Institutes of Health · USQueen's Hospital · GBRoyal Gwent Hospital · GBUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

Medical Research Council MR/Y008219/1
6 · The paper itself

Abstract

Background: Seed amplification assay (SAA) testing has become an important biomarker in the diagnosis of alpha-synuclein related neurodegenerative disorders. Objectives: To assess the rate of alpha-synuclein SAA positivity in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), and analyse the clinical and pathological features of SAA positive and negative cases. Methods: 106 CSF samples from clinically diagnosed PSP (n=59), CBS (n=37) and indeterminate parkinsonism cases (n=10) were analysed using alpha-synuclein SAA. Results: Three cases (1 PSP, 2 CBS) were Multiple System Atrophy (MSA)-type SAA positive. 5/59 (8.5%) PSP cases were Parkinson's disease (PD)-type SAA positive, and these cases were older and had a shorter disease duration compared with SAA negative cases. In contrast, 9/35 (25.7%) CBS cases were PD-type SAA positive. Conclusions: Our results suggest that PD-type seeds can be detected in PSP and CBS using a CSF alpha-synuclein SAA, and in PSP this may impact on clinical course.

Identifiers

PMID38529496
PMCPMC10962751
OpenAlexW4392299526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.